Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOV28A)

• Drug Name: Plamotamab Drug Info
• Synonyms: XmAb 13676

Indication

Disease Entry	ICD 11	Status	REF
Diffuse large B-cell lymphoma	2A81	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMOV28A

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[4]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[5]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[6]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[7]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[8]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[9]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[10]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[11]
TAK-280	DM08RE5	Aggressive cancer	2A00-2F9Z	Phase 2	[12]

Drug(s) Targeting Leukocyte surface antigen Leu-16 (CD20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[4]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[5]
Ibritumomab	DMG594T	Non-hodgkin lymphoma	2B33.5	Approved	[14]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[15]
Ublituximab	DMHTY9W	Multiple sclerosis	8A40	Approved	[16]
Tositumomab	DMMYZ3D	Non-hodgkin lymphoma	2B33.5	Approved	[14]
Obinutuzumab	DM3BVAE	Chronic lymphocytic leukaemia	2A82.0	Approved	[17]
Ofatumumab	DM295PR	Chronic lymphocytic leukaemia	2A82.0	Approved	[18]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Not Available	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT05328102) A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb13676 (Plamotamab) Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. U.S.National Institutes of Health.
• [2] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [5] Clinical pipeline report, company report or official report of Genmab.
• [6] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [7] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [8] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [9] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [10] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [11] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [12] ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
• [15] [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
• [16] The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [18] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [19] Clinical pipeline report, company report or official report of Genentech (2009).